Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:5/25/2011

EAST SETAUKET, N.Y., May 25, 2011 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert B. Royds, M.B., B.S., M.R.C.P. to the company's Board of Directors.

Dr. Royds is Chair of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, which he founded in 1982.  Theradex®, based in Princeton, NJ, with research bases in Europe, Australia, and Japan, provides a full complement of services critical to drug development including regulatory strategy, consulting, pre-clinical toxicology and pharmacology review, preparation of regulatory filings, and clinical trials design.  Dr. Royds is responsible for the scientific affairs of the company.  

Trained in internal medicine and pharmacology, Dr. Royds has extensive experience in all stages of clinical drug development process. Before founding Theradex®, he was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. He has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. He has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.  

"We are extremely pleased that Dr. Royds has joined our Board of Directors.  He has had an exceptional experience in all aspects of cancer drug development, especially in the increasingly complex area of efficient clinical evaluation of new anti-cancer drugs with diverse clinical applications," said Dr. Kovach.  "Dr. Royds' expertise is particularly valuable to Lixte at this juncture in the clinical development of our lead compounds, especially, LB-100, a novel signal transduction modifier, which has activity against different types of human cancer, alone but especially, in combination with standard  anti-cancer drugs.      

About Lixte Biotechnology Holdings, Inc.

Lixte is a biotechnology company engaged in development of improved treatments for cancer and methods for detecting cancer. Lixte was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past four years, however, the Company has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to develop new potentially more effective anti-cancer drugs.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The primary focus is on the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme ("GBM"). The research on brain tumors is being conducted with the National Institute of Neurological Disorders and Stroke ("NINDS") of the National Institutes of Health ("NIH") under a Cooperative Research and Development Agreement ("CRADA").

The Company has expanded the scope of its program to other cancers of neural tissue (nerve and brain), including medulloblastoma, the most common brain tumor of children, and neuroblastoma, the most common cancer of children, and to other common cancers of adults including sarcomas, melanomas, and breast cancer

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10-QSB for the quarter ending March 31, 2011.

For additional information, please see:
www.Lixte.com

Investor Relations
Jeff Ramson
212-297-6103
jramson@proactivecrg.com
Pro-Active Capital Resources Group


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
2. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
4. Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy
5. Goodwin Biotechnology and RAFAGEN Announce a Collaboration
6. Reportlinker Adds Industrial Biotechnology China News 1104
7. Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland
8. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
9. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
10. Reportlinker Adds Industrial Biotechnology China News 1103
11. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):